Alto Neuroscience Inc. (ANRO) Stock Price

ANROStock
$35.13+822.05%52W
Market Cap$1.38B
P/E
PEG Ratio
Div yield
Beta1.23

ANRO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)69.90%
Price vs S&P 500 (4W)27.28%
VGM Score85.10

ANRO Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.77-$0.65+15.95%(+$0.12)
Q1 2026-$0.51-$0.80-58.42%(-$0.30)
Q4 2025-$0.51-$0.45+11.76%(+$0.06)
Q3 2025-$0.64-$0.52+18.75%(+$0.12)
Q2 2025-$0.60-$0.65-8.56%(-$0.05)

ANRO Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.31
4.39
4.39
4.38

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
ANROAlto Neuroscience Inc.
A$35.13
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Alto Neuroscience Inc.

Alto Neuroscience is a clinical-stage biopharmaceutical company developing personalized psychiatric treatments guided by brain-based biomarkers. The company's pipeline includes multiple programs targeting major depressive disorder and schizophrenia, with candidates including ALTO-100, ALTO-202, ALTO-101, and ALTO-300. Alto's approach aims to match patients with treatments based on individual neurobiology to improve treatment efficacy in psychiatry.